Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Lea Sewell

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Arthritis|May 17, 2018
Biosimilars Have Arrived: RituximabMaria Greenwald, John Tesser, K Lea Sewell
Postgraduate Medicine|March 28, 2017
Biosimilar biologic drugs: a new frontier in medical careDaniel M Geynisman, Guillermo De Velasco, K Lea Sewell, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 26, 2016
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published EvidenceIra Jacobs, Danielle Petersel, Leah Isakov, et al.
Patient Preference and Adherence|June 17, 2016
Patient attitudes and understanding about biosimilars: an international cross-sectional surveyIra Jacobs, Ena Singh, K Lea Sewell, et al.
British Journal of Clinical Pharmacology|April 15, 2020
A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testingKai H Liao, Chandrasekhar Udata, Donghua Yin, et al.
Antisense & Nucleic Acid Drug Development|April 15, 2003
Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimensRosie Z Yu, John Q Su, John S Grundy, et al.
Arthritis Research & Therapy|August 17, 2018
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritisRoy M Fleischmann, Rieke Alten, Margarita Pileckyte, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alphaK Lea Sewell, Richard S Geary, Brenda F Baker, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 5, 2010
Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuriaSharon G Adler, Sherwyn Schwartz, Mark E Williams, et al.
Arthritis Research & Therapy|July 29, 2018
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapyStanley B Cohen, Rieke Alten, Hideto Kameda, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Arthritis|May 17, 2018
Biosimilars Have Arrived: RituximabMaria Greenwald, John Tesser, K Lea Sewell
Postgraduate Medicine|March 28, 2017
Biosimilar biologic drugs: a new frontier in medical careDaniel M Geynisman, Guillermo De Velasco, K Lea Sewell, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 26, 2016
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published EvidenceIra Jacobs, Danielle Petersel, Leah Isakov, et al.
Patient Preference and Adherence|June 17, 2016
Patient attitudes and understanding about biosimilars: an international cross-sectional surveyIra Jacobs, Ena Singh, K Lea Sewell, et al.
British Journal of Clinical Pharmacology|April 15, 2020
A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testingKai H Liao, Chandrasekhar Udata, Donghua Yin, et al.
Antisense & Nucleic Acid Drug Development|April 15, 2003
Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimensRosie Z Yu, John Q Su, John S Grundy, et al.
Arthritis Research & Therapy|August 17, 2018
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritisRoy M Fleischmann, Rieke Alten, Margarita Pileckyte, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alphaK Lea Sewell, Richard S Geary, Brenda F Baker, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 5, 2010
Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuriaSharon G Adler, Sherwyn Schwartz, Mark E Williams, et al.
Arthritis Research & Therapy|July 29, 2018
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapyStanley B Cohen, Rieke Alten, Hideto Kameda, et al.
Pageof 1